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KIT and PDGFRA are receptor tyrosine kinases that can be specifically inactivated by small-molecule tyrosine kinase inhibitors, notably
imatinib mesylate. In ovarian carcinoma, expression of KIT and PDGFRA protein has been documented, but the frequency and the
molecular background of expression are poorly known. We analysed the expression of KIT and PDGFRA by immunohistochemistry
in 522 serous ovarian carcinomas, and mutations of KIT and PDGFRA by denaturing high-performance liquid chromatographyin 125
and 187 serous ovarian carcinomas, respectively. No mutations of KIT or PDGFRA were detected. KIT expression was detected in
12% of carcinomas: low expression in 10% and high expression in 2% of cases. Using normal serous epithelium as a reference,
decreased PDGFRA expression was detected in 12% and increased expression in 13% of carcinomas. Both KIT and PDGFRA
expression were associated with high tumour grade, high proliferation index and poor patient outcome. By fluorescence in situ
hybridisation, no KIT amplification was found in carcinomas with high KIT expression, but two cases showed a relative gain of
chromosome 4. In conclusion, no mutations of KIT or PDGFRA were found, but a subset of serous ovarian carcinoma showed
overexpression of the proteins, which was associated with aggressive tumour characteristics.
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Most cases of ovarian carcinoma are disseminated at the time of
the diagnosis requiring postoperative chemotherapy. Currently,
combination chemotherapy using taxanes and platinum-based
drugs is the standard treatment. Initially, majority of the patients
respond to treatment, but ultimately over half of them experience
disease recurrence and at this phase tumours are frequently
resistant to currently used chemotherapy regimens. Thus, more
effective treatment options against advanced ovarian carcinoma
are needed.
KIT and PDGFRA belong to type III receptor tyrosine kinases,
and they can be specifically targeted by tyrosine kinase inhibitors
such as imatinib mesylate (STI571) (Fletcher, 2004). Somatic gain-
of-function mutation of KIT has been documented in several
human malignancies, notably acute myelogenous leukaemia,
systemic mast cell disease, germ cell tumours and gastrointestinal
stromal tumours (GIST) (Heinrich et al, 2002). KIT mutation has a
key role in the pathogenesis of GISTs as demonstrated by the
clinical effect of imatinib mesylate (Demetri et al, 2002). A subset
of GISTs that lack KIT mutation harbour PDGFRA mutations and
have shown response to imatinib therapy as well (Heinrich et al,
2003). In addition to point mutations, PDGFRA is activated by
other mechanisms such as gene amplification in glioblastoma and
chromosomal translocation leading to fusion protein formation in
certain myeloproliferative diseases (Fletcher, 2004).
KIT and PDGFRA are not ubiquitous proteins, but their
expression has also been reported in some epithelial malignancies
including in ovarian carcinoma. This has raised hopes that some
carcinomas could be treated with imatinib mesylate. In ovarian
carcinomas, the reported frequency of KIT and PDGFRA expres-
sion has been highly variable, and little is known about their
molecular background and association with clinical parameters
(Henriksen et al, 1993; Inoue et al, 1994; Arber et al, 1998; Dabrow
et al, 1998; Parrott et al, 2000; Tonary et al, 2000; Schmandt et al,
2003; Singer et al, 2003; Apte et al, 2004a; Matei et al, 2004). GISTs
with KIT mutation, particularly in exon 11, show a clearly better
response to imatinib therapy as compared to tumours with no
mutation, suggesting that detection of gain-of-function mutation
and not solely KIT expression should be a requirement for the
treatment (Heinrich et al, 2003).
Ovarian carcinoma is a heterogeneous disease as regards tumour
histology. In previous literature, different histological types, mainly
serous, mucinous and endometrioid, have been treated as a single
entity, but lately they have been shown to differ in their
clinicopathological characteristics (Makar et al, 1995; Risch et al,
1996; Heintz et al, 2001) and molecular alterations (Klemi et al,
1995; Tapper et al, 1997; Obata et al, 1998; Lassus et al, 2001;
Schwartz et al,2 0 0 2 ) .I nt h i ss t u d y ,w eh a v ec o n c e n t r a t e do no n e
histological type, serous carcinoma, which is the most common
subtype of ovarian carcinoma and shows aggressive behaviour and
secondary resistance to currently used adjuvant therapy.
To evaluate the molecular basis for use of imatinib mesylate in
ovarian carcinoma, we analysed the frequency of KIT and PDGFRA
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ymutations by denaturing high-performance liquid chromatogra-
phy (DHPLC) and direct sequencing of aberrant exons in 125 and
187 serous ovarian carcinoma specimens, respectively. Protein
expression status of KIT and PDGFRA was performed by
immunohistochemistry of tissue microarray containing 522 serous
ovarian carcinomas. Tumours showing aberrantly high expression
of KIT were further tested for KIT amplification by fluorescence in
situ hybridisation (FISH). The findings were correlated with
clinicopathological and other molecular characteristics of the
tumours and outcome of the patients.
MATERIALS AND METHODS
Mutation analysis
Tumour samples were obtained from patients undergoing primary
surgery for ovarian carcinoma at the Department of Obstetrics and
Gynecology, Helsinki University Central Hospital. Tumours with
serous histology and tumour cell percentage over 60 (range 60–95,
median 75%) were included in the study. Borderline tumours were
excluded from the study, but otherwise the cases were not selected
for stage or grade. KIT mutation analysis was performed from 111
fresh–frozen and from 14 paraffin-embedded samples, and
PDGFRA mutation analysis from 187 fresh–frozen tumour
samples. DNA was extracted from tumour tissue block after
mechanical disruption directly (fresh–frozen samples) or after
xylene extraction (paraffin-embedded samples). A standard
proteinase-K–phenol–chloroform method was used for DNA
extraction.
PCR conditions for mutational analysis
Exons of 9, 11, 13 and 17 of KIT and exons 11 and 17 of PDGFRA
(according to the Human Genome Project available at http://
www.ensembl.org; exons 11 and 17 correspond to PDGFRA exons
12 and 18 of GenBank Accession number D50013, http://
www.ncbi.nlm.nih.gov:80/entrez/) were amplified from tumour
samples using primers given in Table 1. PCR was performed in
50ml reactions consisting of 20–50ng genomic DNA, 0.2mM
dNTPs, 1  PCR buffer (Gibco BRL, Gaithersburg, MD), 4.5mM
MgCl2, 0.5U Platinum Taq DNA polymerase (Gibco BRL), 0.5U
AmpliTaq Gold (Applied Biosystems) and 10pmol of each forward
and reverse primer (Gibco BRL). PCR cycles consisted of 951C for
14min, followed by 35 cycles of 30s at 951C, 30s at 551C for exons
of KIT/591C for exons of PDGFRA, 45s at 721C and a final
extension at 721C for 5min. Subsequently, the PCR fragments were
analysed with DHPLC.
Denaturing high-performance liquid chromatography
PCR products were denatured for 3min at 951C and then
reannealed gradually over 30min using a 951Ct o4 0 1C temperature
gradient. The optimal melting temperature for each PCR amplicon
was obtained by analysis of the wild-type sequence, using
an algorithm at the Stanford Denaturing High-Performance
Liquid Chromatography website (http://insertion.stanford.edu/
melt.html). DHPLC heteroduplex analysis was performed using
an automated HPLC instrumentation (Agilent Technologies)
equipped with a Helix DNA column (Varian Inc., Netherlands).
The analytical gradient was composed of Buffer A (100mM
triethylammonium acetate and 0.10mM EDTA) and Buffer B
(100mM triethylammonium acetate, 0.10mM EDTA and 25%
acetonitrile) with a flow rate of 0.450mlmin
 1. The injection
volume of each PCR sample was 4–7ml. The analysis time for each
sample was 7min, including a short column wash and an
equilibration step. GISTs harbouring mutations in exons 9, 11 or
17 (KIT) and 11 or 17 (PDGFRA) were used as positive controls for
DHPLC analysis.
Protein expression analysis by immunohistochemistry
Material and tissue microarray construction Material for protein
expression analysis consisted of 522 serous ovarian carcinomas,
which have been characterised previously (Lassus et al, 2003).
Tissue microarrays were constructed as described previously
(Kononen et al, 1998). Tissue specimens from 34 normal ovarian
and 23 normal fallopian tube samples and 522 serous ovarian
carcinomas were arranged in six recipient paraffin blocks. Four
core tissue biopsies were obtained from each specimen (Lassus
et al, 2003).
Immunohistochemistry Sections (5mm thick) were cut from each
block on coated slides. The sections were deparaffinised in xylene
and rehydrated through graded concentrations of ethanol. The
slides were pretreated with citrate buffer (pH 6.0) in a microwave
oven for 2 4min and then cooled for 30min before starting the
staining procedure, which was performed for KIT in Dako
Autostainer with the Envision System and for PDGFRA in Lab
Vision Autostainer with the Ultravision System. The primary
antibodies used were a polyclonal antibody against KIT (dilution
1:100; Dako, Carpinteria, CA, USA) and a polyclonal antibody
against synthetic peptide derived from C-terminal of PDGFRA
(dilution 1:150, Neomarkers, Lab Vision, Fremont, CA, USA).
Negative controls were performed by replacing the primary
antibody by normal rabbit serum. For KIT paraffin-embedded
KIT-positive GISTs were used as positive controls.
The immunohistochemical analysis was evaluated by a pathol-
ogist (RB) without knowledge of the clinicopathological informa-
tion. The epithelium of fallopian tubes (the normal serous
epithelium of Mu ¨llerian origin) and ovarian surface epithelium
(OSE) were used as a reference of normal expression for both
proteins. Both membrane and cytoplasmic staining were taken into
account and scored according to the intensity as follows: KIT –
negative, weak or strong; and PDGFRA – weak, moderate or
strong.
Table 1 Primers used for PCR of exons of 9, 11, 13 and 17 of KIT and exons 11 and 17 of PDGFRA
Exon Forward primer Reverse primer
KIT
9 GTATGCCACATCCCAAGTGT CATGACTGATATGGTAGACA
11 CCAGAGTGCTCTAATGACTG GGAAGCCACTGGAGTTCCTT
13 GACATCAGTTTGCCAGTTGT TGTTTTGATAACCTGACAGAC
17 GCAACACTATAGTATTAAAAAG CCTTTGCAGGACTGTCAAGCA
PDGFRA
11 ATGTGGAGTGAACGTTGTTGG CTAGTTCTTACTAAGCACAAGC
17 CAGGGGTGATGCTATTCAGC TTAAAGTGAAGGAGGATGAGCC
KIT and PDGFRA in serous ovarian carcinoma
H Lassus et al
2049
British Journal of Cancer (2004) 91(12), 2048–2055 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yImmunohistochemistry for p53 and Ki-67 was performed as
described previously (Lassus et al, 2004). A polyclonal antibody
against Ki-67 (1:150, clone N/A; code A0047; Dako A/S, Glostrup,
Denmark) and a monoclonal antibody against p53 (1:100; clone
DO-7; Dako A/S, Glostrup, Denmark) were used as primary
antibodies.
Fluorescence in situ hybridisation
Paraffin-embedded samples of tumours showing distinct, strong
KIT staining by immunohistochemistry were included in the FISH
analysis.
Chromosome 4 was studied with a centromere-specific probe
(CEP4 Spectrum Green, Vysis Inc., North Chicago, IL), and KIT
gene with BAC probes (clones RP11-1106L19 and RP11-977G3).
The correct probe identities were confirmed using PCR with the
KIT-specific primers. The BAC-DNAs were isolated using routine
techniques and labelled with DIG-Nick translation mix (Roche,
Mannheim, Germany). The dual-colour hybridisations were
performed as described previously (Hyytinen et al, 1994). The
digoxigenin-labelled probes were detected by sheep anti-digox-
igenin–rhodamine antibody (Roche, Mannheim, Germany).
Interphase nuclei were prepared as described previously
(Hyytinen et al, 1994). KIT probe and chromosome 4 centromere
probe were cohybridised and after hybridisation, counterstained
with DAPI and viewed under a fluorescence microscopy equipped
with ISIS digital image analysis system (MetaSystems). Approxi-
mately 50 interphase nuclei were analysed of each sample and
percentages/subpopulation were calculated for normal and abnor-
mal nuclei.
DNA ploidy analysis
Core tissue biopsy specimen (diameter 0.8mm) were taken
from areas representing carcinoma in paraffin tissue block. The
tissue cores were deparaffinised, rehydrated and DNA flow
cytometry was performed as described previously (Jahkola et al,
1998).
Statistical analysis
Associations between factors were analysed with the w
2 and
Fisher’s exact tests. The overall and disease-free survival curves
were constructed according to the Kaplan–Meier method and
compared with the log-rank test. For multivariate survival analysis
Cox’s proportional-hazards model was used, with backward
stepwise selection procedure, and entering the following as
categorial covariates: FIGO stage (stages I, II, III and IV), grade
(grades 1, 2 and 3), age at diagnosis (o57 years (median) and X57
years), tumour size (p10cm and 410cm), residual tumour size
(p1cm and 41cm), ascites (presence or absence), p53 expression
(normal and aberrant) and Ki-67 expression (0–10, 10–25 and
425%). A P-value of 0.05 was adopted as the limit for inclusion of
a covariate. All P-values are two-sided.
RESULTS
Mutation analysis of KIT and PDGFRA
In DNA from freshly frozen tissue samples, DHPLC analysis of at
least one exon failed in approximately 5% of cases due to poor
amplification of the sample DNA. Out of 14 paraffin-embedded
tumours, 11 were successfully analysed. In cases of aberrant
DHPLC profile, the analysis was repeated and doubtful cases were
sequenced. For KIT analysis, exons 9 and 13 were sequenced in two
samples. For PDGFRA analysis, exon 17 was sequenced in one
sample and exon 11 in five samples. No sequence alterations were
found.
KIT expression and clinicopathological associations
The epithelium of normal ovarian surface and fallopian tubes was
negative for KIT protein (Figure 1A and B). In the stroma of
fallopian tubes, there were single cells with strong cytoplasmic
staining (Figure 1B), compatible with mast cells. The stromal cells
of normal ovarian cortex showed variable, mainly weak, positivity
(Figure 1A). KIT immunostaining was interpretable in 516 (99%)
of the 522 serous ovarian carcinomas. No staining (negative) was
AB C D E
F G H I J
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Figure 1 Examples of KIT and PDGFRA expression by immunohistochemistry. Normal ovarian surface (A) and tubal (B) epithelium showing negative
immunostaining of KIT protein. Serous ovarian carcinomas showing negative (C), weak (D) and strong (E) staining of KIT protein. Normal OSE showing
negative immunostaining of PDGFRA (F) and tubal epithelium showing moderate immunopositivity of PDGFRA (G). Serous ovarian carcinomas showing
weak (H), moderate (I) and strong (J) staining of PDGFRA.
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and strong positive immunostaining in 12 (2.3%) of the
interpretable cases (Figure 1C–E).
KIT expression was associated with high tumour grade
(Po0.0001), advanced age (P¼0.0198), high proliferation index
(P¼0.0004) and aberrant p53 status (P¼0.0053), but not with
tumour stage, tumour size, residual tumour size or the presence of
ascites (Table 2).
Patients with tumours showing KIT expression (low or high)
were associated with shorter overall survival compared with cases
showing negative KIT expression (Figure 2A). The 5-year overall
survival rates for patients with tumours with negative, weak
positive and strong positive KIT expression were 50% (95% CI,
45–55%), 34% (19–50%) and 35% (3–66%), respectively. When
tumours with low and high KIT expression were analysed as one
group (positive KIT expression), the difference was statistically
significant (P¼0.0414). There was also a tendency for a shorter
disease-free survival in patients with positive KIT expression, but
the association was not statistically significant (P¼0.0875).
PDGFRA expression and clinicopathological associations
The epithelium of normal ovarian surface was negative for
PDGFRA expression (Figure 1F), whereas the serous epithelium
of fallopian tubes showed variable, moderate immunopositivity
(Figure 1G). PDGFRA immunostaining was interpretable in 505
(97%) of the 522 serous ovarian carcinomas. Weak positive
immunostaining was detected in 59 (12%), moderate immunos-
taining, corresponding to that of fallopian tube epithelium, in 382
(75%) and strong immunostaining in 64 (13%) of the interpretable
cases (Figure 1H–J).
Strong PDGFRA staining was associated with high tumour grade
(P¼0.0019), high tumour stage (P¼0.0483), large residual tumour
size (P¼0.0330) and high proliferation index (P¼0.0060), but not
with advanced age, tumour size, presence of ascites or p53 status
(Table 3). PDGFRA expression was not associated with KIT
expression (P¼0.13).
High PDGFRA expression was associated with shorter overall
survival (P¼0.0353) (Figure 2B). The 5-year overall survival rates
for patients with tumours with low, moderate and high PDGFRA
expression were 49% (95% CI, 34–63%), 51% (46–57%) and 31%
(19–43%), respectively. PDGFRA expression was also associated
with disease-free survival (P¼0.0003) (Figure 2C). The 5-year
disease-free survival rates for patients with tumours with low,
moderate and high PDGFRA expression were 90% (95% CI, 76–
100%), 70% (64–77%) and 39% (21–57%), respectively.
KIT and chromosome 4 copy number by FISH
FISH analysis was successful in 10 out of 12 tumours showing
high KIT expression. Six of these 10 tumours showed a normal
copy number (two signals) for both chromosome 4 centromere
Table 2 Association of KIT expression with clinicopathological characteristics
KIT immunohistochemical score
Clinicopathological characteristics Negative % Weak positive % Strong positive % P-value
FIGO stage
I 100/108 93 5/108 4 3/108 3 NS; 0.39
II 56/64 87 8/64 13 0/64 0
III 243/281 86 31/281 11 7/281 2
IV 51/60 85 7/60 12 2/60 3
Grade
1 186/194 96 5/194 3 3/194 2 o0.0001
2 110/132 83 20/132 15 2/132 2
3 150/182 82 25/182 14 7/182 4
Residual tumour
p1cm 201/236 85 27/236 11 8/236 3 NS; 0.23
41cm 204/228 89 21/228 9 3/228 1
Age
p57 years 229/249 92 16/249 6 4/249 2 0.0198
457 years 224/267 84 35/267 13 8/267 3
Tumour size
p10cm 158/179 88 16/179 9 5/179 3 NS; 0.83
410cm 287/327 88 33//327 10 7/327 2
Ascites
No 168/185 91 14/185 8 3/185 2 NS; 0.29
Yes 277/322 86 37/322 11 8/322 2
Ki-67
Low (0–10%) 253/270 94 14/270 5 3/270 1 0.0004
Moderate (10–25%) 106/130 82 19/130 15 5/130 4
High (425%) 80/101 79 17/101 17 4/101 4
p53
Normal 192/206 93 10/206 5 4/206 2 0.0053
Aberrant 248/295 84 40/295 14 7/295 2
NS¼not significant.
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of nuclei with tetrasomy, one tumour had a subpopulation of
nuclei with five FISH-signals for both probes and one tumour
showed a subpopulation with seven FISH signals for both
probes (Figure 3A). One tumour showed a loss of other
chromosome 4 and KIT gene (Figure 3B). No high-level
amplification was observed in any of the tumours analysed. The
results of FISH and ploidy analysis of these tumours are shown in
Table 4.
DISCUSSION
No KIT or PDGFRA mutations were found in serous ovarian
carcinomas. In our analysis, we concentrated on the juxtamem-
brane and catalytic domains, that is, exons 9, 11, 13 and 17 of KIT
and exons 11 and 17 of PDGFRA, where the activating mutations in
KIT and PDGFRA have been detected (Heinrich et al, 2002;
Heinrich et al, 2003). As regards KIT, our finding extends the
previous observation of no mutations in 50 ovarian carcinomas of
different histological types (Singer et al, 2003). As regards
PDGFRA, to our knowledge, no previous reports on ovarian
carcinoma exist in the literature.
KIT expression in normal ovaries and ovarian carcinomas has
been addressed in several previous studies with highly variable
results. At least one study (Parrott et al, 2000) reported KIT
immunoreactivity in normal OSE, but most reports do not confirm
this finding (Inoue et al, 1994; Tonary et al, 2000; Schmandt et al,
2003; Singer et al, 2003). In our analysis both OSE and fallopian
tube epithelium, the normal serous epithelium of Mu ¨llerian origin,
were negative for KIT protein. Many reports have indicated high
frequency (71–100%) of KIT expression in ovarian carcinomas
(Arber et al, 1998; Parrott et al, 2000; Tonary et al, 2000), whereas
others have shown lower levels of expression (0–22%) (Inoue et al,
1994; Schmandt et al, 2003; Singer et al, 2003). We found the
expression of KIT protein in 12% of serous ovarian carcinomas:
10% showed low and 2% high expression of the protein.
Disparities in the findings of different studies may reflect
heterogeneity in the study material as regards tumour histology
and other clinicopathological parameters. More importantly,
different antibodies and staining protocols have been used. Our
findings are closest to those reported by Schmandt et al (2003) and
Singer et al (2003), who also used the KIT CD117 polyclonal
antibody (Dako), which is accepted for clinical use while assessing
the KIT expression in GIST (Fletcher et al, 2002). We used the
same antibody dilution and IHC protocol as routinely used in GIST
diagnostics. Weak expression was found to be mainly cytoplasmic,
whereas in strongly positive cases, membranous staining was also
detected, presumably representing the active form of KIT protein
(Tian et al, 1999; Shaw et al, 2002).
KIT expression was associated with poor histological differ-
entiation, high patient age and poor patient outcome. The
association of KIT expression with poor clinical outcome is in
line with the presumed oncogenic properties of KIT. Schmandt et al
(2003) also reported association of KIT expression with high
tumour grade but contradictory findings exist. Tonary et al (2000)
reported KIT expression to be independent of tumour grade, but
associated with low tumour stage and favourable patient outcome.
In that particular study, the frequency of KIT expressing tumours
was very high (71%), indicating differences in the methodology
and material employed. In our study, tumours with KIT expression
more often presented with high proliferation index and aberrant
p53 status. Interestingly, the associations of KIT expression with
grade, age, Ki-67 and p53 were independent of the degree of KIT
expression (low or high). The association of KIT with high growth
fraction is consistent with presumed proliferation promoting effect
of KIT. However, in ovarian carcinoma cell lines, KIT inhibition by
anti-KIT neutralising antibodies or the KIT inhibitor STI571 did
not alter the growth rate (Shaw et al, 2002). The real biological role
of KIT in ovarian carcinoma cells remains to be clarified.
The normal OSE did not express PDGFRA protein, which is in
line with previous findings (Henriksen et al, 1993). However, the
epithelium of fallopian tubes showed variable, moderate immu-
nopositivity, and similar expression pattern was seen in majority
(75%) of the carcinomas. Using this as a reference, 12% of serous
ovarian carcinomas showed decreased and 13% increased
PDGFRA expression. In previous reports, PDGFRA immunoposi-
tivity has varied from 5 to 100% of ovarian carcinomas (Henriksen
et al, 1993; Dabrow et al, 1998; Apte et al, 2004a; Matei et al, 2004).
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Figure 2 Overall survival in patients with serous ovarian carcinoma in
relation to KIT expression (A) and PDGFRA expression (B)b y
immunohistochemistry. Disease-free survival in patients with serous ovarian
carcinoma in relation to PDGFRA expression (C).
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meters. Henriksen et al (1993) also found PDGFRA positivity to
associate with poor overall survival. In our study, the association
with disease-free survival was even stronger than that with
overall survival. In line with aggressive tumour behaviour,
PDGFRA expression was also associated with high tumour
grade and stage, large residual tumour size and high proliferation
index.
In all, 12 carcinomas presented with distinct KIT overexpression
and amplification of KIT gene was considered as a possible
mechanism for overexpression. However, FISH analysis revealed
no gene amplification. Six tumours out of 10 showed a normal
copy number, three showed polysomy and one monosomy of
chromosome 4. In two tumours showing five and seven copies of
chromosome 4, the tumour cells were diploid/hyperdiploid,
indicating a relative gain of chromosome 4. In two cases, there
was a relative loss of chromosome 4: one with monosomy of
chromosome 4 and diploid DNA and the other with two copies of
chromosome 4 and hypertetraploid DNA. KIT gene is located at
the proximal part of chromosome arm 4q (4q11–12). According to
cytogenetic and comparative genomic hybridisation studies, gain
of chromosome 4 is a very rare event in ovarian carcinoma.
The relative gain of chromosome 4 we observed in two out
of 10 tumours is an unexpected finding (http://cgap.nci.nih.gov/
Chromosomes/RecurrentAberrations; http://ethesis.helsinki.fi/
julkaisut/laa/kliin/vk/lassus/) and may account for the overexpres-
sion of KIT in these cases. Interstitial chromosomal deletion on
4q12 yielding active fusion protein FIPIL1-PDGFRA plays a causal
role in a portion of idiopathic hypereosinophilia syndrome and
chronic eosinophilic leukaemia cases that can successfully be
treated with imatinib mesylate (Coutre and Gotlib, 2004).
Interestingly, loss of chromosomal material from 4q is frequent
in serous ovarian carcinoma (reviewed in http://ethesis.helsinki.fi/
julkaisut/laa/kliin/vk/lassus/) and gain-of-function deletion is an
intriguing alternative mechanism for PDGFRA overexpression.
Table 3 Association of PDGFRA expression with clinicopathological characteristics
PDGFRA immunohistochemical score
Clinicopathological characteristics Weak % Moderate % Strong % P-value
FIGO stage
I 12/58 21 83/380 22 9/64 14 0.0483
II 12/58 21 44/380 12 10/64 16
III 23/58 40 208/380 55 41/64 64
IV 11/58 19 45/380 12 4/64 6
Grade
1 22/59 37 153/375 41 13/63 21 0.0019
2 11/59 19 103/375 27 15/63 24
3 26/59 44 119/375 32 35/63 56
Residual tumour
p1cm 24/49 49 178/345 51 20/60 33 0.0330
41cm 25/49 51 167/345 49 40/60 67
Age
o57 years 29/59 49 185/382 48 31/64 48 NS; 0.99
X57 years 30/59 51 197/382 52 33/64 52
Tumour size
p10cm 26/58 45 122/377 32 23/61 38 NS; 0.15
410cm 32/58 55 255/377 68 38/61 62
Ascites
No 26/56 46 130/377 34 22/63 35 NS; 0.22
Yes 30/56 54 247/377 66 41/63 65
Ki-67
0–10% 39/57 68 200/375 53 24/62 39 0.0060
10–25% 9/57 16 105/375 28 17/62 27
425% 9/57 16 70/375 19 21/62 34
p53
Normal 27/58 47 155/372 42 17/63 27 NS; 0.053
Aberrant 31/58 53 217/372 58 46/63 73
NS¼not significant.
Figure 3 Examples of copy number analysis of KIT gene and
chromosome 4 centromere by FISH: serous ovarian carcinomas showing
a subpopulation of cells with seven signals for both probes (case 2283) (A)
and a loss of other chromosome 4 and KIT gene (case 1029) (B).
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regards potential usefulness of imatinib mesylate in serous
ovarian carcinoma. In GISTs (KIT and PDGFRA mutations),
breast carcinoma (HER-2 amplification) and lung cancer (EGFR
mutation), targeted therapy has yielded best results in cases
with activating mutation or amplification of the respective gene
(Vogel et al, 2002; Heinrich et al, 2003; Lynch et al, 2004).
However, in our study, both KIT and PDGFRA expression
were associated with aggressive tumour characteristics, such as
high tumour grade, high proliferation index and poor
patient outcome, suggesting them a role in the pathophysiology
of at least a subset of serous ovarian carcinomas. Accordingly,
imatinib mesylate has inhibited growth of ovarian cancer
cells through PDGFRA and Akt inactivation (Matei et al, 2004),
and combination therapy of imatinib–paclitaxel has impaired
progression of ovarian cancer in peritoneal cavity of nude mice
and lead to increased apoptosis of tumour-associated end-
othelial cells (Apte et al, 2004b). The possible usefulness of
imatinib mesylate in the treatment of ovarian carcinoma can
only be resolved in clinical trials. If such were to be conducted,
KIT or PDGFRA overexpression, and not mutational status
of the genes, would seem as appropriate criteria for selection of
patients.
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